Centene Corp.

Centene is one of the largest Medicaid managed-care companies in the US — running state Medicaid contracts plus a Medicare Advantage business (WellCare, Fidelis) and TRICARE managed-care contracts for military families. The equity is up 104% year-over-year on real earnings-beat cycles, sitting at 97% of yearly range.

• The Q1 beat was exceptional: Q1 revenue grew 7.1% YoY to $49.9B at a 22% gross margin and 3.7% operating margin, but Q1 EPS of $3.37 crushed the $2.23 estimate by 51% — that's the operating-margin-recovery arriving in reported numbers, and the four-quarter beat pattern (2-445% surprise range) is the classic post-drawdown consensus-under-modeling signal.
• The valuation is genuinely compressed given the acceleration: 5.2x trailing P/E (looks distorted due to negative TTM earnings), but forward P/E of ~19x on FY26 EPS $3.50 with a 19% free cash flow yield is where a mid-tier managed-care name should trade — that's the setup where the multiple has room to expand.
• The AI-driven Medicaid-eligibility work is the underappreciated angle: Centene's integrated-healthcare model plus the operating-efficiency work (reducing administrative costs while maintaining medical-loss-ratio discipline) is what's driving the sustained earnings-beat cycle — that's the durable margin story.
• Insider tape is fully routine: multiple July 1 A-Awards to directors (Tyler, Tanji, Samuels, Eppinger) plus new director Lauren Tyler (JPMorgan HR veteran) joining the board is standard board-level activity — no distribution cluster to worry about, and the acceleration continues.

July 28 print is the confirmation. A beat with FY26 EPS guide raised above $3.50 combined with continued Medicaid-margin improvement breaks toward $80+; a soft Aetna-adjacent competitive commentary or Medicaid rate-review commentary is what tests $60 support. At forward P/E of 19x on 51% earnings surprise, the setup remains buyable.